Search

Your search keyword '"Naleway A"' showing total 727 results
Start Over Author "Naleway A" Search Limiters Peer Reviewed
727 results on '"Naleway A"'

2. Redirecting antibody responses from egg-adapted epitopes following repeat vaccination with recombinant or cell culture-based versus egg-based influenza vaccines

Author

Liu, Feng, Gross, F. Liaini, Joshi, Sneha, Gaglani, Manjusha, Naleway, Allison L., Murthy, Kempapura, Groom, Holly C., Wesley, Meredith G., Edwards, Laura J., Grant, Lauren, Kim, Sara S., Sambhara, Suryaprakash, Gangappa, Shivaprakash, Tumpey, Terrence, Thompson, Mark G., Fry, Alicia M., Flannery, Brendan, Dawood, Fatimah S., and Levine, Min Z.

Published
2024
Full Text
View/download PDF

3. Attitudes toward a future norovirus vaccine among members of an integrated healthcare delivery system in Portland, Oregon, 2016-2017

Author

Holly C. Groom, Mark Schmidt, Laura E. Calderwood, Sara A. Mirza, Claire Mattison, Suzanne Salas, Judy Donald, and Allison L. Naleway

Subjects
Norovirus, vaccine attitudes, acute gastroenteritis, Immunologic diseases. Allergy, RC581-607, Therapeutics. Pharmacology, RM1-950
Abstract

ABSTRACTWith recent advances in U.S. clinical trials for norovirus vaccines, it is an opportune time to examine what is known about the public receptivity to this novel vaccine. From October 2016–September 2017, we surveyed Kaiser Permanente Northwest members in Portland, Oregon, to ask their level of agreement on a 5-point scale with statements about the need for and willingness to get a potential norovirus vaccine for themselves or their child and analyzed their responses according to age, occupational status, prior vaccine uptake, and history of prior norovirus diagnoses. The survey response rate was 13.5% (n = 3,894); 807 (21%) responded as legal guardians, on behalf of a child

Published
2024
Full Text
View/download PDF

6. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis

Author

Payne, Amanda B, Watts, Janet A, Mitchell, Patrick K, Dascomb, Kristin, Irving, Stephanie A, Klein, Nicola P, Grannis, Shaun J, Ong, Toan C, Ball, Sarah W, DeSilva, Malini B, Natarajan, Karthik, Sheffield, Tamara, Bride, Daniel, Arndorfer, Julie, Naleway, Allison L, Koppolu, Padma, Fireman, Bruce, Zerbo, Ousseny, Timbol, Julius, Goddard, Kristin, Dixon, Brian E, Fadel, William F, Rogerson, Colin, Allen, Katie S, Rao, Suchitra, Mayer, David, Barron, Michelle, Reese, Sarah E, Rowley, Elizabeth A K, Najdowski, Morgan, Ciesla, Allison Avrich, Mak, Josephine, Reeves, Emily L, Akinsete, Omobosola O, McEvoy, Charlene E, Essien, Inih J, Tenforde, Mark W, Fleming-Dutra, Katherine E, and Link-Gelles, Ruth

Published
2024
Full Text
View/download PDF

8. Frequency of medically attended adverse events following tetanus and diphtheria toxoid vaccine in adolescents and young adults: a Vaccine Safety Datalink study

Author

Naleway Allison, Baxter Roger, Nelson Jennifer, Hambidge Simon J, Belongia Edward A, Yu Onchee, Jackson Lisa A, Gay Charlene, Nordin James, Baggs James, and Iskander John

Subjects
Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Local reactions are the most commonly reported adverse events following tetanus and diphtheria toxoid (Td) vaccine and the risk of local reactions may increase with number of prior Td vaccinations. Methods To estimate the risk of medically attended local reactions following Td vaccination in adolescents and young adults we conducted a six-year retrospective cohort study assessing 436,828 Td vaccinations given to persons 9 through 25 years of age in the Vaccine Safety Datalink population from 1999 through 2004. Results Overall, the estimated risk of a medically attended local reaction was 3.6 events per 10,000 Td vaccinations. The lowest risk (2.8 events per 10,000 vaccinations) was found in the 11 to 15 year old age group. In comparison with that group, the event risks were significantly higher in both the 9 to 10 and 21 to 25 year old age groups. The risk of a local reaction was significantly higher in persons who had received another tetanus and diphtheria toxoid containing vaccine (TDCV) in the previous five years (incidence rate ratio, 2.9; 95% confidence interval, 1.2 to 7.2). Twenty-eight percent of persons with a local reaction to Td vaccine were prescribed antibiotics. Conclusion Medically attended local reactions were uncommon following Td vaccination. The risk of those reactions varied by age and by prior receipt of TDCVs. These findings provide a point of reference for future evaluations of the safety profile of newer vaccines containing tetanus or diphtheria toxoid.

Published
2009
Full Text
View/download PDF

9. Patterns of pneumococcal vaccination and revaccination in elderly and non-elderly adults: a Vaccine Safety Datalink study

Author

Belongia Edward A, Naleway Allison L, Baxter Roger, Jackson Lisa A, and Baggs James

Subjects
Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Pneumococcal polysaccharide vaccine (PPV) is recommended for all adults 65 years of age and older and for younger adults with high-risk conditions. While data from national surveys provide information on the proportion of adults 65 years of age and older reporting ever receipt of PPV they do not collect more detailed information, such as age at vaccination or the total number of vaccinations received. In addition, there is relatively little information available on PPV coverage in younger adults with chronic conditions. To assess contemporary patterns of pneumococcal vaccination and revaccination of adults, we conducted a cross-sectional study of adults enrolled in medical care organizations (MCOs) participating in the Vaccine Safety Datalink project. Methods The study population included 1.5 million adults 25 years of age and older enrolled in the four participating MCOs on December 1, 2006. PPVs administered to members of the study population prior to that date were identified from computerized immunization registries maintained by the MCOs. Results Among the general population of adults 25 through 64 years of age, vaccine coverage increased from 2% in the 25–29 year old age-group to 26% in the 60–64 year old age-group. In all age-groups, coverage was substantially higher in persons defined as having a chronic high risk condition. This was particularly true for diabetes mellitus, with vaccine coverage of over 50% in the lower age-groups and 75% in those 60–64 years of age. Among adults 65 years of age and older, 82% had received at least one PPV and 18% had received two or more PPVs. Conclusion We found higher levels of PPV coverage among adults 65 years of age and older and among younger adults with diabetes mellitus than reported by national surveys and for those groups PPV coverage approached the Healthy People 2010 national objectives. These results suggest that achieving those objectives for PPV is possible and that high vaccination coverage may be facilitated by vaccine tracking and reminder systems.

Published
2009
Full Text
View/download PDF

10. Serum per- and polyfluoroalkyl substance concentrations and longitudinal change in post-infection and post-vaccination SARS-CoV-2 antibodies

Author

Hollister, James, Caban-Martinez, Alberto J., Ellingson, Katherine D., Beitel, Shawn, Fowlkes, Ashley L., Lutrick, Karen, Tyner, Harmony L., Naleway, Allison L., Yoon, Sarang K., Gaglani, Manjusha, Hunt, Danielle, Meece, Jennifer, Mayo Lamberte, Julie, Schaefer Solle, Natasha, Rose, Spencer, Dunnigan, Kayan, Khan, Sana M., Kuntz, Jennifer L., Fisher, Julia M., Coleman, Alissa, Britton, Amadea, Thiese, Matthew S., Hegmann, Kurt T., Pavuk, Marian, Ramadan, Ferris A., Fuller, Sammantha, Nematollahi, Amy, Sprissler, Ryan, and Burgess, Jefferey L.

Published
2023
Full Text
View/download PDF

12. Racial and ethnic disparities in influenza vaccination coverage among pregnant women in the United States: The contribution of vaccine-related attitudes

Author

Daley, Matthew F., Reifler, Liza M., Shoup, Jo Ann, Glanz, Jason M., Naleway, Allison L., Nelson, Jennifer C., Williams, Joshua T.B., McLean, Huong Q., Vazquez-Benitez, Gabriela, Goddard, Kristin, Lewin, Bruno J., Weintraub, Eric S., McNeil, Michael M., Razzaghi, Hilda, and Singleton, James A.

Published
2023
Full Text
View/download PDF

13. Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021–February 2022, VISION Network: a retrospective cohort study

Author

Adams, Katherine, Riddles, John J., Rowley, Elizabeth A.K., Grannis, Shaun J., Gaglani, Manjusha, Fireman, Bruce, Hartmann, Emily, Naleway, Allison L., Stenehjem, Edward, Hughes, Alexandria, Dalton, Alexandra F., Natarajan, Karthik, Dascomb, Kristin, Raiyani, Chandni, Irving, Stephanie A., Sloan-Aagard, Chantel, Kharbanda, Anupam B., DeSilva, Malini B., Dixon, Brian E., Ong, Toan C., Keller, Jean, Dickerson, Monica, Grisel, Nancy, Murthy, Kempapura, Nanez, Juan, Fadel, William F., Ball, Sarah W., Patel, Palak, Arndorfer, Julie, Mamawala, Mufaddal, Valvi, Nimish R., Dunne, Margaret M., Griggs, Eric P., Embi, Peter J., Thompson, Mark G., Link-Gelles, Ruth, and Tenforde, Mark W.

Published
2023
Full Text
View/download PDF

16. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021

Author

Bozio, Catherine H., Grannis, Shaun J., Naleway, Allison L., Ong, Toan C., Butterfield, Kristen A., DeSilva, Malini B., Natarajan, Karthik, Yang, Duck-Hye, Rao, Suchitra, Klein, Nicola P., Irving, Stephanie A., Dixon, Brian E., Dascomb, Kristin, Liao, I-Chia, Reynolds, Sue, McEvoy, Charlene, Han, Jungmi, Reese, Sarah E., Lewis, Ned, Fadel, William F., Grisel, Nancy, Murthy, Kempapura, Ferdinands, Jill, Kharbanda, Anupam B., Mitchell, Patrick K., Goddard, Kristin, Embi, Peter J., Arndorfer, Julie, Raiyani, Chandni, Patel, Palak, Rowley, Elizabeth A., Fireman, Bruce, Valvi, Nimish R., Griggs, Eric P., Levy, Matthew E., Zerbo, Ousseny, Porter, Rachael M., Birch, Rebecca J., Blanton, Lenee, Ball, Sarah W., Steffens, Andrea, Olson, Natalie, Williams, Jeremiah, Dickerson, Monica, McMorrow, Meredith, Schrag, Stephanie J., Verani, Jennifer R., Fry, Alicia M., Azziz-Baumgartner, Eduardo, Barron, Michelle, Gaglani, Manjusha, Thompson, Mark G., and Stenehjem, Edward

Published
2021

17. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021

Author

Embi, Peter J., Levy, Matthew E., Naleway, Allison L., Patel, Palak, Gaglani, Manjusha, Natarajan, Karthik, Dascomb, Kristin, Ong, Toan C., Klein, Nicola P., Liao, I-Chia, Grannis, Shaun J., Han, Jungmi, Stenehjem, Edward, Dunne, Margaret M., Lewis, Ned, Irving, Stephanie A., Rao, Suchitra, McEvoy, Charlene, Bozio, Catherine H., Murthy, Kempapura, Dixon, Brian E., Grisel, Nancy, Yang, Duck-Hye, Goddard, Kristin, Kharbanda, Anupam B., Reynolds, Sue, Raiyani, Chandni, Fadel, William F., Arndorfer, Julie, Rowley, Elizabeth A., Fireman, Bruce, Ferdinands, Jill, Valvi, Nimish R., Ball, Sarah W., Zerbo, Ousseny, Griggs, Eric P., Mitchell, Patrick K., Porter, Rachael M., Kiduko, Salome A., Blanton, Lenee, Zhuang, Yan, Steffens, Andrea, Reese, Sarah E., Olson, Natalie, Williams, Jeremiah, Dickerson, Monica, McMorrow, Meredith, Schrag, Stephanie J., Verani, Jennifer R., Fry, Alicia M., Azziz-Baumgartner, Eduardo, Barron, Michelle A., Thompson, Mark G., and DeSilva, Malini B.

Published
2021

19. CASCADIA: a prospective community-based study protocol for assessing SARS-CoV-2 vaccine effectiveness in children and adults using a remote nasal swab collection and web-based survey design

Author

Jeremy Stone, Richard A Mularski, Sarah N Cox, Mark A Schmidt, Helen Y Chu, Janet A Englund, Peter D Han, Caitlin R Wolf, Stephen P Fortmann, Sharon Saydah, Ning Smith, Marco Carone, Claire M Midgley, Allison L Naleway, Melissa Briggs-Hagen, Jennifer L Kuntz, Tara M Babu, Leora R Feldstein, Zachary Acker, Cassandra L Boisvert, Amanda Casto, Brenna Ehmen, Collrane J Frivold, Holly Groom, Tina Lockwood, Tara Ogilvie, Sacha L Reich, Lea Starita, Meredith Vandermeer, and Ana A Weil

Subjects
Medicine
Abstract

Introduction Although SARS-CoV-2 vaccines were first approved under Emergency Use Authorization by the Food and Drug Administration in late 2020 for adults, authorisation for young children 6 months to 6 months and adults aged

Published
2023
Full Text
View/download PDF

20. COVID-19 Vaccination Coverage Among Insured Persons Aged ≥16 Years, by Race/Ethnicity and Other Selected Characteristics — Eight Integrated Health Care Organizations, United States, December 14, 2020–May 15, 2021

Author

Pingali, Cassandra, Meghani, Mehreen, Razzaghi, Hilda, Lamias, Mark J., Weintraub, Eric, Kenigsberg, Tat’Yana A., Klein, Nicola P., Lewis, Ned, Fireman, Bruce, Zerbo, Ousseny, Bartlett, Joan, Goddard, Kristin, Donahue, James, Hanson, Kayla, Naleway, Allison, Kharbanda, Elyse O., Yih, W. Katherine, Nelson, Jennifer Clark, Lewin, Bruno J., Williams, Joshua T.B., Glanz, Jason M., Singleton, James A., and Patel, Suchita A.

Published
2021

21. COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy — Eight Integrated Health Care Organizations, United States, December 14, 2020–May 8, 2021

Author

Razzaghi, Hilda, Meghani, Mehreen, Pingali, Cassandra, Crane, Bradley, Naleway, Allison, Weintraub, Eric, Kenigsberg, Tat’Yana A., Lamias, Mark J., Irving, Stephanie A., Kauffman, Tia L., Vesco, Kimberly K., Daley, Matthew F., DeSilva, Malini, Donahue, James, Getahun, Darios, Glenn, Sungching, Hambidge, Simon J., Jackson, Lisa, Lipkind, Heather S., Nelson, Jennifer, Zerbo, Ousseny, Oduyebo, Titilope, Singleton, James A., and Patel, Suchita A.

Published
2021

24. Risk reduction in SARS-CoV-2 infection and reinfection conferred by humoral antibody levels among essential workers during Omicron predominance.

Author

Hollister, James, Porter, Cynthia, Sprissler, Ryan, Beitel, Shawn C., Romine, James K., Uhrlaub, Jennifer L., Grant, Lauren, Yoo, Young M., Fowlkes, Ashley, Britton, Amadea, Olsho, Lauren E. W., Newes-Adeyi, Gabriella, Fuller, Sammantha, Zheng, Pearl Q., Gaglani, Manjusha, Rose, Spencer, Dunnigan, Kayan, Naleway, Allison L., Gwynn, Lisa, and Caban-Martinez, Alberto

Subjects
SARS-CoV-2 Omicron variant, BLOOD testing, COVID-19 vaccines, LOGISTIC regression analysis, REINFECTION
Abstract

The extent to which semi-quantitative antibody levels confer protection against SARS-CoV-2 infection in populations with heterogenous immune histories is unclear. Two nested case-control studies were designed within the multisite HEROES/RECOVER prospective cohort of frontline workers to study the relationship between antibody levels and protection against first-time post-vaccination infection and reinfection with SARS-CoV-2 from December 2021 to January 2023. All participants submitted weekly nasal swabs for rRT-PCR testing and blood samples quarterly and following infection or vaccination. Cases of first-time post-vaccination infection following a third dose of monovalent (origin strain WA-1) mRNA vaccine (n = 613) and reinfection (n = 350) were 1:1 matched to controls based on timing of blood draw and other potential confounders. Conditional logistic regression models were fit to estimate infection risk reductions associated with 3-fold increases in end titers for receptor binding domain (RBD). In first-time post-vaccination and reinfection study samples, most were female (67%, 57%), non-Hispanic (82%, 68%), and without chronic conditions (65%, 65%). The odds of first-time post-vaccination infection were reduced by 21% (aOR = 0.79, 95% CI = [0.66–0.96]) for each 3-fold increase in RBD end titers. The odds of reinfection associated with a 3-fold increase in RBD end titers were reduced by 23% (aOR = 0.77, 95% CI = [0.65–0.92] for unvaccinated individuals and 58% (aOR = 0.42, 95% CI = [0.22–0.84]) for individuals with three mRNA vaccine doses following their first infection. Frontline workers with higher antibody levels following a third dose of mRNA COVID-19 vaccine were at reduced risk of SARS-CoV-2 during Omicron predominance. Among those with previous infections, the point estimates of risk reduction associated with antibody levels was greater for those with three vaccine doses compared to those who were unvaccinated. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Care trajectories for patients utilizing electronic visits for COVID-like symptoms in a large healthcare delivery system: May 2020–December 2021.

Author

Groom, Holly C, Crawford, Phil, Azziz-Baumgartner, Eduardo, Henninger, Michelle L, Smith, Ning, Salas, Bianca, Donald, Judy, and Naleway, Allison L

Subjects
MEDICAL care, COVID-19, ELECTRONIC health records, DIGITAL health, OUTPATIENT medical care
Abstract

Background: There is limited information about how on-line screening tools developed by integrated systems facilitated management of COVID-like illness patients. Methods: Using the Kaiser Permanente Northwest (KPNW) Electronic Health Record, we identified adult plan members who accessed online COVID-19 screening e-visits and enumerated their subsequent medical encounters, tests for SARS-CoV-2, and test outcomes. Results: Between May 2020 and December 2021, members completed 55,139 e-visits, with disproportionate representation among females (65% vs. 53% in the overall membership) and members aged <45 years (61% vs. 39%). Thirty percent of patients (16,953) were managed entirely through e-visits and 70% received subsequent in-person care. The percent of SARS-CoV-2 positive individuals was highest among the 1055 individuals triaged to inpatient care (17.9%), compared to 9.5% among those escalated to additional ambulatory care. Conclusions: The e-visit on-line screening tool helped KPNW assist thousands of patients with COVID-19 symptoms, avoid unnecessary in-person patient encounters, and preserved KPNW infection control and pandemic surge capacity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Abnormal uterine bleeding diagnoses and care following COVID-19 vaccination

Author

DeNoble, Anna E., DeSilva, Malini, Ellington, Sascha, Henninger, Michelle, Jazwa, Amelia, Kharbanda, Elyse, Lipkind, Heather, Malden, Debbie, McNeil, Michael M., Tartof, Sara, Zerbo, Ousseny, Brooks, Neon, Irving, Stephanie A., Kauffman, Tia L., Vesco, Kimberly K., Slaughter, Matthew, Smith, Ning, Tepper, Naomi K., Olson, Christine K., Weintraub, Eric S., and Naleway, Allison L.

Published
2024
Full Text
View/download PDF

28. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

Author

Thompson, Mark G., Burgess, Jefferey L., Naleway, Allison L., Tyner, Harmony L., Yoon, Sarang K., Meece, Jennifer, Olsho, Lauren E.W., Caban-Martinez, Alberto J., Fowlkes, Ashley, Lutrick, Karen, Kuntz, Jennifer L., Dunnigan, Kayan, Odean, Marilyn J., Hegmann, Kurt T., Stefanski, Elisha, Edwards, Laura J., Schaefer-Solle, Natasha, Grant, Lauren, Ellingson, Katherine, Groom, Holly C., Zunie, Tnelda, Thiese, Matthew S., Ivacic, Lynn, Wesley, Meredith G., Lamberte, Julie Mayo, Sun, Xiaoxiao, Smith, Michael E., Phillips, Andrew L., Groover, Kimberly D., Yoo, Young M., Gerald, Joe, Brown, Rachel T., Herring, Meghan K., Joseph, Gregory, Beitel, Shawn, Morrill, Tyler C., Mak, Josephine, Rivers, Patrick, Harris, Katherine M., Hunt, Danielle R., Arvay, Melissa L., Kutty, Preeta, Fry, Alicia M., and Gaglani, Manjusha

Published
2021

30. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—Nine States, January–September 2021

Author

Embi, Peter J., Levy, Matthew E., Naleway, Allison L., Patel, Palak, Gaglani, Manjusha, Natarajan, Karthik, Dascomb, Kristin, Ong, Toan C., Klein, Nicola P., Liao, I-Chia, Grannis, Shaun J., Han, Jungmi, Stenehjem, Edward, Dunne, Margaret M., Lewis, Ned, Irving, Stephanie A., Rao, Suchitra, McEvoy, Charlene, Bozio, Catherine H., Murthy, Kempapura, Dixon, Brian E., Grisel, Nancy, Yang, Duck-Hye, Goddard, Kristin, Kharbanda, Anupam B., Reynolds, Sue, Raiyani, Chandni, Fadel, William F., Arndorfer, Julie, Rowley, Elizabeth A., Fireman, Bruce, Ferdinands, Jill, Valvi, Nimish R., Ball, Sarah W., Zerbo, Ousseny, Griggs, Eric P., Mitchell, Patrick K., Porter, Rachael M., Kiduko, Salome A., Blanton, Lenee, Zhuang, Yan, Steffens, Andrea, Reese, Sarah E., Olson, Natalie, Williams, Jeremiah, Dickerson, Monica, McMorrow, Meredith, Schrag, Stephanie J., Verani, Jennifer R., Fry, Alicia M., Azziz-Baumgartner, Eduardo, Barron, Michelle A., Thompson, Mark G., and DeSilva, Malini B.

Published
2022
Full Text
View/download PDF

33. Incidence Rates of Medically Attended COVID-19 in Infants Less Than 6 Months of Age

Author

Griffin, Isabel, Irving, Stephanie A., Arriola, Carmen Sofia, Campbell, Angela P., Li, De-Kun, Dawood, Fatimah S., Doughty-Skierski, Caroline, Ferber, Jeannette R., Ferguson, Nickolas, Hadden, Louise, Henderson, Jillian T., Juergens, Mary, Kancharla, Venkatesh, Naleway, Allison L., Newes-Adeyi, Gabriella, Nicholson, Erin, Odouli, Roxana, Reichle, Lawrence, Sanyang, Mo, Woodworth, Kate, and Munoz, Flor M.

Published
2023
Full Text
View/download PDF

35. Postmenopausal bleeding after COVID-19 vaccination

Author

Crane, Brad, Mittendorf, Kathleen F., Burch, Debra, DeSilva, Malini, Ellington, Sascha, Henninger, Michelle, Jazwa, Amelia, Kharbanda, Elyse, Lipkind, Heather, Malden, Debbie, McNeil, ; Michael M., Suh-Burgmann, Betty, Tartof, Sara, Zerbo, Ousseny, Kauffman, Tia L., Irving, Stephanie A., Brooks, Neon, Vesco, Kimberly K., Slaughter, Matthew, Smith, Ning, Tepper, Naomi K., Olson, Christine K., Weintraub, Eric S., and Naleway, Allison L.

Published
2024
Full Text
View/download PDF

37. Classification Accuracy and Description of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in an Integrated Health Care System, 2006-2017.

Author

Liles, Elizabeth G., Irving, Stephanie A., Koppolu, Padma, Crane, Bradley, Naleway, Allison L., Brooks, Neon B., Gee, Julianne, Unger, Elizabeth R., and Henninger, Michelle L.

Subjects
INTEGRATED health care delivery, ELECTRONIC health records, NOSOLOGY, CHRONIC fatigue syndrome, CHRONIC diseases
Abstract

INTRODUCTION: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic illness characterized by marked functional limitations and fatigue. Electronic health records can be used to estimate incidence of ME/CFS but may have limitations. METHODS: The authors used International Classification of Diseases (ICD) diagnosis codes to identify all presumptive cases of ME/CFS among 9- to 39-year-olds from 2006 to 2017. The authors randomly selected 200 cases for medical record review to classify cases as confirmed, probable, or possible, based on which and how many current clinical criteria they met, and to further characterize their illness. The authors calculated crude annual rates of ME/CFS coding stratified by age and sex using only those ICD codes that had identified confirmed, probable, or possible ME/CFS cases in the medical record review. RESULTS: The authors identified 522 individuals with presumptive ME/CFS based on having = 1 ICD codes for ME/CFS in their electronic medical record. Of the 200 cases selected, records were available and reviewed for 188. Thirty (15%) were confirmed or probable ME/CFS cases, 39 (19%) were possible cases, 119 (60%) were not cases, and 12 (6%) had no medical record available. Confirmed/probable cases commonly had chronic pain (80%) or anxiety/depression (70%), and only 13 (43%) had completed a sleep study. Overall, 37 per 100,000 had ICD codes that identified confirmed, probable, or possible ME/CFS. Rates increased between 2006 and 2017, with the largest absolute increase among those 30-39 years old. CONCLUSIONS: Using ICD diagnosis codes alone inaccurately estimates ME/CFS incidence. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Effectiveness of the Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters in Pregnant Persons Who Were Not Immunocompromised: VISION Network, June 2022–August 2023.

Author

Ciesla, Allison Avrich, Lazariu, Victoria, Dascomb, Kristin, Irving, Stephanie A, Dixon, Brian E, Gaglani, Manjusha, Naleway, Allison L, Grannis, Shaun J, Ball, Sarah, Kharbanda, Anupam B, Vazquez-Benitez, Gabriela, Klein, Nicola P, Natarajan, Karthik, Ong, Toan C, Embi, Peter J, Fleming-Dutra, Katherine E, Link-Gelles, Ruth, and Zerbo, Ousseny

Subjects
PREGNANT women, VACCINE effectiveness, COVID-19 vaccines, OUTPATIENT medical care, COVID-19
Abstract

Pregnant people face increased risk of severe COVID-19. Current guidelines recommend updated COVID-19 vaccination (2023–2024) for those aged ≥6 months, irrespective of pregnancy status. To refine recommendations for pregnant people, further data are needed. Using a test-negative design, we evaluated COVID-19 vaccine effectiveness against medically attended COVID-19 with COVID-19–like illness among pregnant people aged 18 to 45 years during June 2022 to August 2023. When doses were received during pregnancy, vaccine effectiveness was 52% (95% CI, 29%–67%); when received <6 months prior to pregnancy, 28% (95% CI, 11%–42%); and when received ≥6 months prior to pregnancy, 6% (95% CI, −11% to 21%). Pregnant people should stay up-to-date with recommended COVID-19 vaccination. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Detection and Stability of SARS-CoV-2 in Three Self-Collected Specimen Types: Flocked Midturbinate Swab (MTS) in Viral Transport Media, Foam MTS, and Saliva

Author

Vic Veguilla, Ashley L. Fowlkes, Adam Bissonnette, Shawn Beitel, Manjusha Gaglani, Christina A. Porucznik, Melissa S. Stockwell, Harmony L. Tyner, Allison L. Naleway, Sarang K. Yoon, Alberto J. Caban-Martinez, Meredith G. Wesley, Jazmin Duque, Zuha Jeddy, Joseph B. Stanford, Michael Daugherty, Ashton Dixon, Jefferey L. Burgess, Marilyn Odean, Holly C. Groom, Andrew L. Phillips, Natasha Schaefer-Solle, Peenaz Mistry, Melissa A. Rolfes, Mark Thompson, Fatimah S. Dawood, and Jennifer Meece

Subjects
COVID-19, SARS-CoV-2, sensitivity, respiratory specimens, RT-PCR, Microbiology, QR1-502
Abstract

ABSTRACT Respiratory specimen collection materials shortages hampers severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing. We compared specimen alternatives and evaluated SARS-CoV-2 RNA stability under simulated shipping conditions. We compared concordance of RT-PCR detection of SARS-CoV-2 from flocked midturbinate swabs (MTS) in viral transport media (VTM), foam MTS without VTM, and saliva. Specimens were collected between August 2020 and April 2021 from three prospective cohorts. We compared RT-PCR cycle quantification (Cq) for Spike (S), Nucleocapsid (N), and the Open Reading Frame 1ab (ORF) genes for flocked MTS and saliva specimens tested before and after exposure to a range of storage temperatures (4–30°C) and times (2, 3, and 7 days). Of 1,900 illnesses with ≥2 specimen types tested, 335 (18%) had SARS-CoV-2 detected in ≥1 specimen; 304 (91%) were concordant across specimen types. Among illnesses with SARS-CoV-2 detection, 97% (95% confidence interval [CI]: 94–98%) were positive on flocked MTS, 99% (95% CI: 97–100%) on saliva, and 89% (95% CI: 84–93%) on foam MTS. SARS-CoV-2 RNA was detected in flocked MTS and saliva stored up to 30°C for 7 days. All specimen types provided highly concordant SARS-CoV-2 results. These findings support a range of viable options for specimen types, collection, and transport methods that may facilitate SARS-CoV-2 testing during supply and personnel shortages. IMPORTANCE Findings from this analysis indicate that (1) self-collection of flocked and foam MTS and saliva samples is feasible in both adults and children, (2) foam MTS with VTM and saliva are both viable and reasonable alternatives to traditional flocked MTS in VTM for SARS-CoV-2 detection, and (3) these sample types may be stored and transported at ambient temperatures for up to 7 days without compromising sample quality. These findings support methods of sample collection for SARS-CoV-2 detection that may facilitate widespread community testing in the setting of supply and personnel shortages during the current pandemic.

Published
2022
Full Text
View/download PDF

45. Reply to Skowronski, De Serres, and Orenstein

Author

Thompson, Mark G., Jackson, Michael L., Regan, Annette, Katz, Mark A., Kwong, Jeffrey C., Ball, Sarah W., Simmonds, Kimberley, Klein, Nicola P., and Naleway, Allison

Published
2019

46. Influenza Vaccine Effectiveness in Preventing Influenza-associated Hospitalizations During Pregnancy : A Multicountry Retrospective Test Negative Design Study, 2010–2016

Author

Thompson, Mark G., Kwong, Jeffrey C., Regan, Annette K., Katz, Mark A., Drews, Steven J., Azziz-Baumgartner, Eduardo, Klein, Nicola P., Chung, Hannah, Effler, Paul V., Feldman, Becca S., Simmonds, Kimberley, Wyant, Brandy E., Dawood, Fatimah S., Jackson, Michael L., Fell, Deshayne B., Levy, Avram, Barda, Noam, Svenson, Lawrence W., Fink, Rebecca V., Ball, Sarah W., and Naleway, Allison

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results